Epigenetics and miRNAs in the diagnosis and treatment of multiple sclerosis

Trends in Molecular Medicine

Volumn 19, Issue 1, 2013, Pages 23-30

  Koch, Marcus W ^a   Metz, Luanne M ^a   Kovalchuk, Olga ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF LETHBRIDGE   (Canada)

Author keywords

Biomarkers; Diagnosis; Epigenetics; Multiple sclerosis; Treatment; Treatment response

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER; GLATIRAMER; MICRORNA; NATALIZUMAB; TRICHOSTATIN A;

ALLERGIC ENCEPHALOMYELITIS; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEOSOME; REVIEW; UNSPECIFIED SIDE EFFECT;

BIOLOGICAL MARKERS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HUMANS; MICRORNAS; MULTIPLE SCLEROSIS;

EID: 84871716263     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.10.008     Document Type: Review

References (79)

1. Noseworthy J.H., et al. Multiple sclerosis. N. Engl. J. Med. 2000, 343:938-952.
2. Handel A.E., et al. Epigenetics: molecular mechanisms and implications for disease. Trends Mol. Med. 2010, 16:7-16.
3. Jirtle R.L., Skinner M.K. Environmental epigenomics and disease susceptibility. Nat. Rev. Genet. 2007, 8:253-262.
4. Mayer W., et al. Demethylation of the zygotic paternal genome. Nature 2000, 403:501-502.
5. Rassoulzadegan M., et al. RNA-mediated non-mendelian inheritance of an epigenetic change in the mouse. Nature 2006, 441:469-474.
6. Wagner K.D., et al. RNA induction and inheritance of epigenetic cardiac hypertrophy in the mouse. Dev. Cell 2008, 14:962-969.
7. Carton H., et al. Risks of multiple sclerosis in relatives of patients in Flanders, Belgium. J. Neurol. Neurosurg. Psychiatr. 1997, 62:329-333.
8. Sadovnick A.D., et al. Multiple sclerosis: updated risks for relatives. Am. J. Med. Genet. 1988, 29:533-541.
9. Robertson N.P., et al. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain 1996, 119:449-455.
10. Sawcer S., et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
11. Ebers G.C., et al. A population-based study of multiple sclerosis in twins. N. Engl. J. Med. 1986, 315:1638-1642.
12. Willer C.J., et al. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:12877-12882.
13. Ramagopalan S.V., et al. Genetic epidemiology: the use of old and new tools for multiple sclerosis. Trends Neurosci. 2008, 31:645-652.
14. Baranzini S.E., et al. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 2010, 464:1351-1356.
15. Ebers G.C., et al. Parent-of-origin effect in multiple sclerosis: observations in half-siblings. Lancet 2004, 363:1773-1774.
16. Herrera B.M., et al. Parent-of-origin effects in MS: observations from avuncular pairs. Neurology 2008, 71:799-803.
17. Ramagopalan S.V., et al. Parental transmission of HLA-DRB1*15 in multiple sclerosis. Hum. Genet. 2008, 122:661-663.
18. Chao M.J., et al. Parent-of-origin effects at the major histocompatibility complex in multiple sclerosis. Hum. Mol. Genet. 2010, 19:3679-3689.
19. Reik W., Walter J. Genomic imprinting: parental influence on the genome. Nat. Rev. Genet. 2001, 2:21-32.
20. Handel A.E., et al. No evidence for an effect of DNA methylation on multiple sclerosis severity at HLA-DRB1*15 or HLA-DRB5. J. Neuroimmunol. 2010, 223:120-123.
21. Asirvatham A.J., et al. MicroRNA targets in immune genes and the Dicer/Argonaute and ARE machinery components. Mol. Immunol. 2008, 45:1995-2006.
22. Munger K.L., et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
23. Simpson S., et al. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J. Neurol. Neurosurg. Psychiatry 2011, 82:1132-1141.
24. Smolders J., et al. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult. Scler. 2008, 14:1220-1224.
25. Simpson S., et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann. Neurol. 2010, 68:193-203.
26. Pereira F., et al. Vitamin D has wide regulatory effects on histone demethylase genes. Cell Cycle 2012, 11:1081-1089.
27. Hernán M.A., et al. Cigarette smoking and incidence of multiple sclerosis. Am. J. Epidemiol. 2001, 154:69-74.
28. Wan E.S., et al. Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. Hum. Mol. Genet. 2012, 21:3073-3082.
29. Koturbash I., et al. Role of epigenetic events in chemical carcinogenesis - a justification for incorporating epigenetic evaluations in cancer risk assessment. Toxicol. Mech. Methods 2011, 21:289-297.
30. Ma Y.T., et al. Smoking initiation is followed by the early acquisition of epigenetic change in cervical epithelium: a longitudinal study. Br. J. Cancer 2011, 104:1500-1504.
31. Toledo-Rodriguez M., et al. Maternal smoking during pregnancy is associated with epigenetic modifications of the brain-derived neurotrophic factor-6 exon in adolescent offspring. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B:1350-1354.
32. Ito K., et al. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J. 2001, 15:1110-1112.
33. Marczylo E.L., et al. Smoking induces differential miRNA expression in human spermatozoa: a potential transgenerational epigenetic concern?. Epigenetics 2012, 7:432-439.
34. Hou L., et al. Environmental chemicals and microRNAs. Mutat. Res. 2011, 714:105-112.
35. Ascherio A., Munger K.L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 2007, 61:288-299.
36. Handel A.E., et al. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS ONE 2010, 5. pii e12496.
37. Niller H.H., et al. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. Semin. Cancer Biol. 2009, 19:158-164.
38. Jaenisch R., Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 2003, 33(Suppl.):245-254.
39. Skinner M.K., et al. Epigenetic transgenerational actions of environmental factors in disease etiology. Trends Endocrinol. Metab. 2010, 21:214-222.
40. Weber M., Schübeler D. Genomic patterns of DNA methylation: targets and function of an epigenetic mark. Curr. Opin. Cell Biol. 2007, 19:273-280.
41. Goll M.G., Bestor T.H. Eukaryotic cytosine methyltransferases. Annu. Rev. Biochem. 2005, 74:481-514.
42. Okano M., et al. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247-257.
43. Klose R.J., Bird A.P. Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 2006, 31:89-97.
44. Dieker J., Muller S. Epigenetic histone code and autoimmunity. Clin. Rev. Allergy Immunol. 2010, 39:78-84.
45. Bernstein E., Allis C.D. RNA meets chromatin. Genes Dev. 2005, 19:1635-1655.
46. Hwang H-W., Mendell J.T. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br. J. Cancer 2006, 94:776-780.
47. Sevignani C., et al. Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm. Genome 2006, 17:189-202.
48. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
49. Chang T-C., Mendell J.T. microRNAs in vertebrate physiology and human disease. Annu. Rev. Genomics Hum. Genet. 2007, 8:215-239.
50. Fabbri M., et al. Regulatory mechanisms of microRNAs involvement in cancer. Expert Opin. Biol. Ther. 2007, 7:1009-1019.
51. Han L., et al. DNA methylation regulates microRNA expression. Cancer Biol. Ther. 2007, 6:1284-1288.
52. Scott G.K., et al. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 2006, 66:1277-1281.
53. Fan D.N-Y., et al. Histone lysine methyltransferase, SUV39H1, promotes HCC progression and is negatively regulated by microRNA-125b. Hepatology 2012, 10.1002/hep.26083.
54. + T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum. 2011, 63:1376-1386.
55. Huang J., et al. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 2010, 52:60-70.
56. Rottach A., et al. DNA methylation-mediated epigenetic control. J. Cell. Biochem. 2009, 108:43-51.
57. Zhao Q., et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat. Struct. Mol. Biol. 2009, 16:304-311.
58. Fisniku L.K., et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008, 131:808-817.
59. Ban J., et al. Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma. Oncogene 2011, 30:2173-2180.
60. Cho W.C.S., et al. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol. 2011, 8:125-131.
61. Keller A., et al. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS ONE 2009, 4:e7440.
62. Waschbisch A., et al. Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PLoS ONE 2011, 6:e24604.
63. Du C., et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat. Immunol. 2009, 10:1252-1259.
64. O'Connell R.M., et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010, 33:607-619.
65. Kebir H., et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 2007, 13:1173-1175.
66. Segal B.M. Th17 cells in autoimmune demyelinating disease. Semin. Immunopathol. 2010, 32:71-77.
67. Becher B., Segal B.M. T(H)17 cytokines in autoimmune neuro-inflammation. Curr. Opin. Immunol. 2011, 23:707-712.
68. Rusca N., et al. MiR-146a and NF-κB1 regulate mast cell survival and T lymphocyte differentiation. Mol. Cell. Biol. 2012, 32:4432-4444.
69. Danger R., et al. Upregulation of miR-142-3p in peripheral blood mononuclear cells of operationally tolerant patients with a renal transplant. J. Am. Soc. Nephrol. 2012, 23:597-606.
70. Liggett T., et al. Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J. Neurol. Sci. 2010, 290:16-21.
71. Miller A.E., Rhoades R.W. Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs. Curr. Opin. Neurol. 2012, 25(Suppl.):S4-S10.
72. Otaegui D., et al. Differential micro RNA expression in PBMC from multiple sclerosis patients. PLoS ONE 2009, 4:e6309.
73. Issa J-P. Epigenetic changes in the myelodysplastic syndrome. Hematol. Oncol. Clin. North Am. 2010, 24:317-330.
74. Garcia-Manero G. Treatment of higher-risk myelodysplastic syndrome. Semin. Oncol. 2011, 38:673-681.
75. Kuendgen A., et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004, 104:1266-1269.
76. Candelaria M., et al. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Ann. Hematol. 2011, 90:379-387.
77. Faraco G., et al. The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis. Mol. Med. 2011, 17:442-447.
78. Gray S.G., Dangond F. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics 2006, 1:67-75.
79. Camelo S., et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2005, 164:10-21.